Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 119 for:    ZIRCONIUM

Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (Zirconipi)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03313323
Recruitment Status : Recruiting
First Posted : October 18, 2017
Last Update Posted : August 30, 2019
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
A.J.M. van den Eertwegh, VU University Medical Center

Brief Summary:

Rationale:

Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment of metastatic melanoma and significantly increases median overall survival. However, use of this drug is associated with immune related adverse events (IRAEs) like colitis, hepatitis, dermatitis, alveolitis and hypophysitis in 10-40% of the patients. In general IRAEs are manageable by cessation of ipilimumab in combination with treatment with corticosteroids or TNF-alpha blockade but they can be severe or even life-threatening. In addition, treatment with ipilimumab is expensive. Because of the high costs and the potential serious toxicity of ipilimumab, it is of great importance to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from CTLA-4 blockade therapy.

The investigators hypothesize that differences in response to treatment with ipilimumab are due to variability in the pharmacodynamics and -kinetics of the antibody. It is hypothesized that patients who do not respond to treatment with ipilimumab have lower drug levels in tumor tissues as compared to patients with a good response to therapy. In addition, the investigators hypothesize that IRAEs are associated with high drug levels in the affected tissue.

To visualize molecular interactions a novel technique is used in which positron emission tomography (PET) is combined with labeled monoclonal antibodies. Because ipilimumab induces activation of T-lymphocytes it is hypothesized that uptake of 89Zr-ipilimumab in tumor lesions and normal tissue is different (i.e. higher) after the second administration of ipilimumab (3 weeks after first injection). Therefore immuno-PET scans will be performed after the first and after the second injection of ipilimumab.

Objective:

Part one: The primary objective is:

1. To assess uptake (visual and quantitative) of 89Zr-ipilimumab in tumor lesions and biodistribution at two timepoints (at start of ipilimumab therapy and after the second injection 3 weeks later).

The secondary objectives are:

  1. To determine the correlation between tumor targeting of ipilimumab and response to therapy.
  2. To assess uptake (visual and quantitative) of 89Zr-ipilimumab in normal tissues.
  3. To determine de correlation between organ targeting and toxicity

Condition or disease Intervention/treatment Phase
Melanoma Biological: 89Zirconium-labeled ipilimumab Phase 2

Detailed Description:
see above

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 29 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma
Actual Study Start Date : February 16, 2017
Estimated Primary Completion Date : February 16, 2021
Estimated Study Completion Date : February 15, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Zirconium-ipilimumab
Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
Biological: 89Zirconium-labeled ipilimumab
Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.




Primary Outcome Measures :
  1. The detection of 89Zr-ipilimumab in tumor lesions [ Time Frame: 3 weeks ]
    The detection (visual and quantitative) of 89Zr-ipilimumab in tumor lesions (the short axis diameter of a measurable tumor lesion is ≥1 cm. The five largest lesions will be used for evaluation).


Secondary Outcome Measures :
  1. The visual detection of 89Zr-ipilimumab in normal tissue [ Time Frame: 3 weeks ]
    The visual detection of 89Zr-ipilimumab in normal tissue after the first injection of ipilimumab and after the second injection 3 weeks later. Visual: Description of the biodistribution.

  2. The quantitative detection of 89Zr-ipilimumab in normal tissue [ Time Frame: 3 weeks ]
    The quantitative detection of 89Zr-ipilimumab in normal tissue after the first injection of ipilimumab and after the second injection 3 weeks later. Quantitative: The % uptake (of total injected) 89Zr-ipilimumab in normal tissue, measured in VOI's.

  3. Comparison between uptake of 89Zr-ipilimumab [ Time Frame: 3 weeks ]
    Comparison between uptake (SUVmean and SUVpeak) of 89Zr-ipilimumab after the first injection of ipilimumab and after the second injection 3 weeks later.

  4. Clinical outcome (response) [ Time Frame: Every 12 weeks, from date of starting therapy until the date of first documented progression or date of death from any cause, whichever came first. Assessed through study completion, an average of 1 year ]
    Response after starting therapy with ipilimumab at 12 and 24 weeks and every 12 weeks thereafter

  5. Clinical outcome (survival) [ Time Frame: Through study completion, an average of 1 year ]
    Overall survival

  6. Side effects [ Time Frame: Until 30 days after the last immuno-PET scan ]
    • Adverse events using Common Terminology Criteria Adverse Events, version 4.0 (CTCAE 4.0)
    • Correlation between side effects of ipilimumab and uptake of 89Zr-ipilimumab in normal tissue

  7. Pharmacokinetics of 89Zr-ipilimumab [ Time Frame: 144 hours after first injection of 89Zr-ipilimumab ]
    Pharmacokinetics of 89Zr-ipilimumab. The concentration of ipilimumab in blood samples will be measured at t = 5, 30, 60, 120 minutes and 72, 144 hours after injection of 89Zr-ipilimumab in the first three patients.

  8. CTLA-4+CD4+ expression of PBMCs [ Time Frame: Before start of ipilimumab and during treatment, up to 11 weeks ]
  9. Immunohistochemical analysis [ Time Frame: 3 weeks ]
    Immunohistochemical analysis (% of tissue with inflammatory infiltrate and characterization of intratumoral T-lymphocytes (CD4, CD8, HLA-DR, FOX-P3, CTLA-4) of tumor biopsy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced/metastatic melanoma.
  • Scheduled for treatment with ipilimumab.
  • Age ≥ 18 years.
  • Histological or cytological documentation of cancer is required.
  • WHO Performance Status of 0 or 1.
  • At least 1 measurable lesion.
  • Signed informed consent must be obtained prior to any study procedures.
  • Patients must be able to adhere to the study appointments and other protocol requirements.

Exclusion Criteria:

  • Previous exposure to ipilimumab.
  • Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g. cervical cap, condom and diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between study drug and oral contraceptives. Concomitant use of oral and barrier contraceptives is advised. Contraception is necessary for at least 6 months after receiving study drug.
  • Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy during the study or within 4 weeks after starting the study drug.
  • Radiotherapy of target lesions during study or within 4 weeks after starting the study drug. Palliative radiotherapy will be allowed.
  • Major surgery within 28 days of start of study drug.
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results.
  • Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03313323


Contacts
Layout table for location contacts
Contact: Jelle Arts +31 (0)20 4444254 trialoffice-onc@vumc.nl
Contact: Alfonsus JM van den Eertwegh, Prof.dr. +31 (0)20 4444321 vandeneertwegh@amsterdamumc.nl

Locations
Layout table for location information
Netherlands
VU Medical Center Recruiting
Amsterdam, Noord-Holland, Netherlands, 1181HV
Contact: Alfonsus MJ van den Eertwegh, Dr.    +31 (0)20-4444321    vandeneertwegh@vumc.nl   
Sponsors and Collaborators
VU University Medical Center
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Principal Investigator: Alfonsus JM van den Eertwegh, Prof.dr. Amsterdam UMC, location VUmc

Layout table for additonal information
Responsible Party: A.J.M. van den Eertwegh, Principal Investigator, VU University Medical Center
ClinicalTrials.gov Identifier: NCT03313323     History of Changes
Other Study ID Numbers: 2015.300
First Posted: October 18, 2017    Key Record Dates
Last Update Posted: August 30, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by A.J.M. van den Eertwegh, VU University Medical Center:
Immuno-PET
Ipilimumab
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents